Zhou B - Search Results

1

Discovery of 1,8-acridinedione derivatives as novel GCN5 inhibitors via high throughput screening.

Xiong H, Han J, Wang J, Lu W, Wang C, Chen Y, Fulin Lian, Zhang N, Liu YC, Zhang C, Ding H, Jiang H, Lu W, Luo C, Zhou B. Xiong H, et al. Among authors: zhou b. Eur J Med Chem. 2018 May 10;151:740-751. doi: 10.1016/j.ejmech.2018.02.005. Epub 2018 Feb 14. Eur J Med Chem. 2018. PMID: 29665527

2

Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.

Ran X, Zhao Y, Liu L, Bai L, Yang CY, Zhou B, Meagher JL, Chinnaswamy K, Stuckey JA, Wang S. Ran X, et al. Among authors: zhou b. J Med Chem. 2015 Jun 25;58(12):4927-39. doi: 10.1021/acs.jmedchem.5b00613. Epub 2015 Jun 16. J Med Chem. 2015. PMID: 26080064 Free PMC article.

3

Identification of novel small-molecule inhibitors targeting menin-MLL interaction, repurposing the antidiarrheal loperamide.

Yue L, Du J, Ye F, Chen Z, Li L, Lian F, Zhang B, Zhang Y, Jiang H, Chen K, Li Y, Zhou B, Zhang N, Yang Y, Luo C. Yue L, et al. Among authors: zhou b. Org Biomol Chem. 2016 Sep 28;14(36):8503-19. doi: 10.1039/c6ob01248e. Epub 2016 Aug 19. Org Biomol Chem. 2016. PMID: 27541268

4

Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression.

Zhou B, Hu J, Xu F, Chen Z, Bai L, Fernandez-Salas E, Lin M, Liu L, Yang CY, Zhao Y, McEachern D, Przybranowski S, Wen B, Sun D, Wang S. Zhou B, et al. J Med Chem. 2018 Jan 25;61(2):462-481. doi: 10.1021/acs.jmedchem.6b01816. Epub 2017 Mar 24. J Med Chem. 2018. PMID: 28339196 Free PMC article.

5

Discovery and optimization of selective inhibitors of protein arginine methyltransferase 5 by docking-based virtual screening.

Ye Y, Zhang B, Mao R, Zhang C, Wang Y, Xing J, Liu YC, Luo X, Ding H, Yang Y, Zhou B, Jiang H, Chen K, Luo C, Zheng M. Ye Y, et al. Among authors: zhou b. Org Biomol Chem. 2017 May 3;15(17):3648-3661. doi: 10.1039/c7ob00070g. Org Biomol Chem. 2017. PMID: 28397890

6

Structure-Based Discovery of 4-(6-Methoxy-2-methyl-4-(quinolin-4-yl)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole (CD161) as a Potent and Orally Bioavailable BET Bromodomain Inhibitor.

Zhao Y, Bai L, Liu L, McEachern D, Stuckey JA, Meagher JL, Yang CY, Ran X, Zhou B, Hu Y, Li X, Wen B, Zhao T, Li S, Sun D, Wang S. Zhao Y, et al. Among authors: zhou b. J Med Chem. 2017 May 11;60(9):3887-3901. doi: 10.1021/acs.jmedchem.7b00193. Epub 2017 May 2. J Med Chem. 2017. PMID: 28463487 Free PMC article.

7

Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression.

Qin C, Hu Y, Zhou B, Fernandez-Salas E, Yang CY, Liu L, McEachern D, Przybranowski S, Wang M, Stuckey J, Meagher J, Bai L, Chen Z, Lin M, Yang J, Ziazadeh DN, Xu F, Hu J, Xiang W, Huang L, Li S, Wen B, Sun D, Wang S. Qin C, et al. Among authors: zhou b. J Med Chem. 2018 Aug 9;61(15):6685-6704. doi: 10.1021/acs.jmedchem.8b00506. Epub 2018 Jul 18. J Med Chem. 2018. PMID: 30019901 Free PMC article.

8

Discovery and biological evaluation of thiobarbituric derivatives as potent p300/CBP inhibitors.

Lu W, Xiong H, Chen Y, Wang C, Zhang H, Xu P, Han J, Xiao S, Ding H, Chen Z, Lu T, Wang J, Zhang Y, Yue L, Liu YC, Zhang C, Yang Y, Jiang H, Chen K, Zhou B, Luo C. Lu W, et al. Among authors: zhou b. Bioorg Med Chem. 2018 Nov 1;26(20):5397-5407. doi: 10.1016/j.bmc.2018.07.048. Epub 2018 Jul 27. Bioorg Med Chem. 2018. PMID: 30297119

9

Reduced asymmetric dimethylarginine accumulation through inhibition of the type I protein arginine methyltransferases promotes renal fibrosis in obstructed kidneys.

Wu M, Lin P, Li L, Chen D, Yang X, Xu L, Zhou B, Wang C, Zhang Y, Luo C, Ye C. Wu M, et al. Among authors: zhou b. FASEB J. 2019 Jun;33(6):6948-6956. doi: 10.1096/fj.201802585RR. Epub 2019 Mar 6. FASEB J. 2019. PMID: 30840839

Finally, we conclude that ADMA has an antifibrotic effect in obstructed kidneys, and future application of type I PRMT inhibitor should be done cautiously for patients with CKD.-Wu, M., Lin, P., Li, L., Chen, D., Yang, X., Xu, L., Zhou, B., Wang, C., Zhang, Y., Luo, …

Finally, we conclude that ADMA has an antifibrotic effect in obstructed kidneys, and future application of type I PRMT inhibitor should be d …

10

Discovery and biological evaluation of vinylsulfonamide derivatives as highly potent, covalent TEAD autopalmitoylation inhibitors.

Lu W, Wang J, Li Y, Tao H, Xiong H, Lian F, Gao J, Ma H, Lu T, Zhang D, Ye X, Ding H, Yue L, Zhang Y, Tang H, Zhang N, Yang Y, Jiang H, Chen K, Zhou B, Luo C. Lu W, et al. Among authors: zhou b. Eur J Med Chem. 2019 Dec 15;184:111767. doi: 10.1016/j.ejmech.2019.111767. Epub 2019 Oct 9. Eur J Med Chem. 2019. PMID: 31622854

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

11,833 results

Search Page